IQVIA shares have dropped 19.8% over the last six months to $177.52, contrasting with the S&P 500's 12.4% gain. The company's annualized revenue growth of 6.7% over five years fell short of healthcare sector benchmarks, while constant currency revenue growth averaged 4.5% over two years, slightly lagging the sector. Its trailing 12-month free cash flow margin remained unchanged at 12.7% over five years. The stock trades at 13.6 times forward price-to-earnings, but analysts cite shaky fundamentals as presenting too much downside risk.
IQVIA Holdings IncAnalysts cite shaky fundamentals and downside risk; stock underperformed S&P 500 with 19.8% drop.